

DJO Incorporated Announces Financial Results for Third Quarter 2007

SAN DIEGO, Oct 29, 2007 (BUSINESS WIRE) -- DJO Incorporated (NYSE:DJO), a global provider of products and services that promote musculoskeletal and vascular health, today announced financial results for the third quarter of 2007, ended September 29, 2007.

Third Quarter Results

Net revenues for the third quarter of 2007 were \$119.8 million, reflecting an increase of 5.8 percent, compared with net revenues of \$113.2 million in the third quarter of 2006. The third quarter of 2006 included a revenue benefit of approximately \$1.9 million due to a change in shipping terms for certain Aircast products and the clearing of product backorders that were outstanding at the end of the second quarter of 2006 due to the impact of integration activities taking place at that time. Excluding this 2006 revenue benefit, third quarter 2007 revenues increased approximately 7.6 percent from the third quarter of 2006. The third quarters of 2007 and 2006 each included 63 shipping days.

Non-GAAP net income for the third quarter of 2007 was \$8.2 million, or \$0.34 per share, reflecting an increase of 23.9 percent, compared to non-GAAP net income of \$6.6 million, or \$0.28 per share, for the third quarter of 2006. Non-GAAP net income results for the third quarter of 2007 exclude transaction costs related to the Company's planned merger with ReAble Therapeutics (\$1.5 million, net of tax). Non-GAAP results in the third quarter of 2006 excluded the impact of certain charges and expenses related to acquisitions (\$1.4 million, net of tax), and the Company's move into its new corporate headquarters (\$0.8 million, net of tax). Non-GAAP net income for the third quarters of 2007 and 2006 has been reduced by the after-tax effect of non-cash stock-based compensation expense of \$2.3 million, or \$0.09 per share, and \$2.3 million, or \$0.10 per share, respectively. GAAP net income for the third quarters of 2007 and 2006 was \$6.7 million, or \$0.28 per share, and \$4.4 million, or \$0.18 per share, respectively.

The Company defines adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, stock-based compensation expense and certain charges and expenses not deemed to be reflective of the ongoing operations of the Company, as discussed above. Adjusted EBITDA for the third quarter of 2007 was \$31.8 million, or 26.5 percent of net revenues, reflecting an increase of 11.1 percent, compared to adjusted EBITDA of \$28.6 million, or 25.3 percent of net revenues, for the third quarter of 2006.

Nine Month Results

Net revenues for the first nine months of 2007 were \$354.9 million, reflecting an increase of 17.4 percent, compared with net revenues of \$302.3 million for the first nine months of 2006. Revenues for the first nine months of 2007 included full contribution from the Company's Aircast acquisition, which closed April 7, 2006. On a pro forma basis, as if the Aircast acquisition had closed on January 1, 2006, revenue for the first nine months of 2007 reflected growth of approximately 8.5 percent over the corresponding prior year period. The first nine months of 2007 and 2006 each included 191 shipping days.

Non-GAAP net income for the first nine months of 2007 was \$22.3 million, or \$0.93 per share, compared with non-GAAP net income of \$18.2 million, or \$0.78 per share, for the first nine months of 2006. Non-GAAP net income for the first nine months of 2007 and 2006 was reduced by the after-tax effect of stock-based compensation expense of \$5.5 million, or \$0.23 per share, and \$5.3 million, or \$0.23 per share, respectively.

For the first nine months of 2007, in addition to the merger-related adjustments noted above for the third quarter of 2007, non-GAAP net income excludes the impact of certain adjustments that the Company does not believe are reflective of its ongoing operations, including an adjustment to write down raw material inventories (\$0.5 million, net of tax), an increase in the Company's estimates of bad debt reserves required for certain aged accounts receivable from third-party payors and patients (\$2.6 million, net of tax), certain costs and expenses related to the integration of the acquired Aircast business (\$1.2 million, net of tax) and costs related to the settlement of outstanding litigation (\$0.3 million, net of tax). For the first nine months of 2006, non-GAAP net income excluded purchase accounting adjustments to write up acquired company inventories (Axmed and Aircast) to fair value (\$0.9 million, net of tax), certain costs and expenses related to the integration of acquired businesses (\$4.4 million, net of tax), certain costs and expenses related to the Company's move into its new corporate headquarters (\$0.8 million, net of tax), costs related to an arbitration that concluded in the second quarter of 2006 (\$0.4 million, net of tax) and the write-off of previously deferred expenses related to a discontinued acquisition (\$0.1 million, net of tax). GAAP net income for the first nine months of 2007 was \$16.1 million, or \$0.67 per share, compared with GAAP net income of \$11.6 million, or \$0.50 per share, for the first nine months of 2006.

Adjusted EBITDA for the first nine months of 2007 was \$87.0 million, or 24.5 percent of net revenues, reflecting an increase of 22.2 percent, compared to adjusted EBITDA of \$71.2 million, or 23.5 percent of net revenues for the first nine months of 2006.

"We had a busy third quarter at DJO. Our core business continues to perform well with solid top-line growth and improved operating metrics highlighting the quarter. We also completed certain milestones required prior to closing the planned merger with ReAble Therapeutics," said Les Cross, president and CEO.

"Net revenues for the third quarter reached \$119.8 million, growing about 6% over the third quarter of 2006. In the third quarter of 2006, DJO realized a sizable revenue benefit of approximately \$1.9 million within our Domestic Rehabilitation and International business segments, the result of a change in Aircast shipping terms and the clearing of product backorders from the second quarter of 2006. Excluding this revenue benefit last year, revenue growth across the Company was approximately 8% in the third quarter of 2007.

"Our Regeneration segment had a strong quarter with total segment revenue growing over 21% compared to the third quarter of 2006, and with our SpinaLogic(R) product line growing more than 37% over the prior year period. The share gains we continue to realize in the spine stimulation market are the result of our expanding distribution strategy in the U.S. that includes both direct and independent representatives.

"Our International segment also delivered strong revenue growth of approximately 13%, aided by our strategy to broaden our product lines in an expanding geographical footprint of direct distribution and also by favorable changes in foreign exchange rates.

"We were pleased to see solid sequential improvement in our gross profit and operating margins from the second quarter of this year as we made further progress with our cost initiatives. On a non-GAAP basis, our gross profit margin improved sequentially from the second quarter by 120 basis points, to 62.0% of revenues. Similarly, on a non-GAAP basis, our operating margin improved by 140 basis points, to 17.4% of revenues.

"Another highlight of the third quarter was our strong cash flow. We generated approximately \$24.1 million in cash from operations, before the impact of the merger related costs incurred during the quarter. We used this cash and \$3.4 million received from the sale of the vacated Aircast New Jersey manufacturing facility to repay \$25.5 million of debt during the third quarter. Our cash balances at the end of the quarter remained strong at approximately \$12 million.

"We continue to be very excited about the merger of ReAble and DJO, which brings together two leaders in orthopedics and rehabilitation and creates a formidable new organization with complementary product lines and distribution synergies that should provide market opportunities worldwide for both companies' product lines. We are well on our way to closing the transaction. We have completed all necessary approvals with the exception of the approval of our stockholders. The special meeting of our stockholders is scheduled for November 6, 2007. We continue to look forward to a fourth quarter closing."

Recent Business Highlights:

- -- DJO Incorporated entered into a merger agreement with ReAble Therapeutics on July 15, 2007. The merger agreement provides for DJO stockholders to receive \$50.25 per share in cash in a transaction valued at approximately \$1.6 billion.
- -- In August 2007, DJO received accreditation status by the Accreditation Commission for Health Care, Inc. (ACHC), a private, not-for-profit corporation developed by home care and community-based providers to help companies improve their business operations and the quality of patient care.
- -- In August 2007, DJO received FDA market approval for enhanced patient features for its line of OL1000 and SpinaLogic bone growth stimulation products.
- -- In September 2007, DJO was named to the Deloitte & Touche "Technology Fast 50" list of San Diego's fastest growing companies for the fifth year in a row.

About DJO Incorporated

DJO Incorporated is a global provider of solutions for musculoskeletal and vascular health, specializing in rehabilitation and regeneration products for the non-operative orthopedic, spine and vascular markets. Marketed under the Aircast(R), DonJoy (R) and ProCare(R) brands, the Company's broad range of over 750 rehabilitation products, including rigid knee braces, soft goods and cold therapy products, are used in the prevention of injury, in the treatment of chronic conditions and for recovery after surgery or injury. The Company's regeneration products consist of bone growth stimulation devices that are used to treat nonunion fractures and as an adjunct therapy after spinal fusion surgery. The Company's vascular systems products help prevent deep vein thrombosis and pulmonary embolism that can occur after orthopedic and other surgeries. Together, these

products provide solutions throughout the patient's continuum of care. The Company sells its products in the United States and in more than 75 other countries through networks of agents, distributors and its own direct sales force. Customers include orthopedic, podiatric and spine surgeons, orthotic and prosthetic centers, third-party distributors, hospitals, surgery centers, physical therapists, athletic trainers, other healthcare professionals and individual and team athletes. For additional information on the Company, please visit www.diortho.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements relate to, among other things, the Company's pending merger with ReAble Therapeutics, Inc. The words "believe," "should," "expect," "intend," "estimate" and "anticipate," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based on the Company's current expectations and are subject to a number of risks, uncertainties and assumptions, many of which are beyond the Company's ability to control or predict. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Some of the important factors that could adversely impact the pending merger with ReAble Therapeutics, Inc. or the Company's results include disruption to the Company's current plans and operations and potential difficulties in employee retention as a result of the merger; the occurrence of any event, change or other circumstance that could give rise to a termination of the merger agreement announced on July 16, 2007; the outcome of the pending legal proceedings that were instituted against our board of directors, DJO, ReAble and The Blackstone Group, ReAble's parent company, following the announcement of the merger agreement; the inability to complete the merger due to the failure to obtain stockholder approval or the failure to satisfy other conditions to the merger; and the failure to obtain the necessary financing arrangements set forth in the commitment letters received in connection with the merger. Other risk factors are detailed in the Company's Quarterly Report on Form 10-Q for the guarterly period ended June 30, 2007, filed on August 3, 2007, with the Securities and Exchange Commission and may be updated by the Company's other SEC filings, including the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 29, 2007.

Additional Information About the Merger and Where to Find It

In connection with the proposed merger referred to in the press release, DJO filed a definitive proxy statement with the SEC on October 9, 2007. STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT (AND ALL AMENDMENTS AND SUPPLEMENTS TO IT) AND OTHER MATERIALS THAT THE COMPANY MAY FILE WITH THE SEC IN THEIR ENTIRETY WHEN SUCH MATERIALS BECOME AVAILABLE, BECAUSE THE MATERIALS CONTAIN IMPORTANT INFORMATION ABOUT DJO AND THE PROPOSED MERGER. The final proxy statement was mailed to DJO's stockholders. Stockholders are able to obtain free copies of the final proxy statement, as well as the Company's other filings, without charge, at the SEC's Web site (www.sec.gov) when they become available. Copies of the filings may also be obtained without charge from DJO by directing a request to: DJO Incorporated, 1430 Decision Street, Vista, CA, 92081, Attention: Mark Francois, Director of Investor Relations (Tel: 1-760-734-4766, Email: mark.francois@djortho.com).

Participants in the Solicitation

DJO and its directors, executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies from stockholders in respect of the proposed merger referred to in the press release. Information regarding DJO's directors and executive officers is available in DJO's 2006 Annual Report on Form 10-K, filed with the SEC on March 1, 2007 and DJO's proxy statement for its 2007 annual meeting of stockholders, filed with the SEC on April 20, 2007. Additional information regarding the interests of such potential participants was included in the definitive proxy statement filed with the SEC on October 9, 2007 in connection with the Special Meeting of Stockholders.

DJO Incorporated Unaudited Condensed Consolidated Statements of Income (In thousands, except per share data and number of operating days)

	Three Months Ended		
	September 29, 2007	September 30, 2006	
Net revenues Costs of goods sold (A),(B)	\$119,784 45,501	\$113,205 45,340	
Gross profit Operating expenses:	74,283	67,865	

Sales and marketing (A),(B)			35,621		33,398
	\				
General and administrative (A)			11,336		
Research and development (A),(2,018		2,580
Amortization of acquired intar	ngibles		4,503		4,510
Merger costs (A)			2,539		-
Total operating expenses			56,017		53,563
Income from operations			18,266		
Interest expense and other, net			(4,999)		(5,845
Income before income taxes			13,267		
Provision for income taxes			(6,552)		
Net income			6,715		
	:		:======		
Net income per share:					
Basic			0.28		
-12	=				
Diluted			0.28	•	
Non-GAAP diluted net income p		=====	:=====	=====	=====
share (excluding the impact	=				
certain charges and expenses					
related to acquisitions and	5				
certain other charges and ex	xpenses				
not deemed to be reflective					
ongoing operations of the Co	ompany)				
ongoing operations of the Co	ompany)	\$	0.34	\$	0.2
ongoing operations of the Co			0.34	•	
	:			•	
Weighted average shares outstanding	:			•	
Weighted average shares outstanding to	used	=====	23,641	-====	22,96
Weighted average shares outstanding to calculate per share information: Basic	used	=====	23,641	=====	22,96
Weighted average shares outstanding to calculate per share information:	used	=====	23,641 ====== 24,251	=====	22,96 ==== 23,59
Weighted average shares outstanding to calculate per share information: Basic Diluted	used	=====	23,641	=====	22,96 ==== 23,59 =====
Weighted average shares outstanding to calculate per share information: Basic Diluted	used	=====	23,641 ====== 24,251	=====	22,96 ==== 23,59 =====
Weighted average shares outstanding to calculate per share information: Basic Diluted	used	=====	23,641	=====	22,96 ==== 23,59 =====
Weighted average shares outstanding to calculate per share information: Basic Diluted Number of operating days	used :	=====	23,641	=====	22,96 ==== 23,59 ====
Weighted average shares outstanding to calculate per share information: Basic Diluted Number of operating days (A) Includes certain charges and exprelated to acquisitions and certain charges and expenses not deemed to	used:	=====	23,641	=====	22,96 ==== 23,59 ====
Weighted average shares outstanding to calculate per share information: Basic Diluted Number of operating days (A) Includes certain charges and exprelated to acquisitions and certain charges and expenses not deemed to reflective of the ongoing operation	used:	=====	23,641	=====	22,96 ==== 23,59 ====
Weighted average shares outstanding to calculate per share information: Basic Diluted Number of operating days (A) Includes certain charges and exprelated to acquisitions and certain charges and expenses not deemed to reflective of the ongoing operation the Company, as follows (C):	used:	=====	23,641	=====	22,96 ===== 23,59 ==== 6
Weighted average shares outstanding to calculate per share information: Basic Diluted Number of operating days (A) Includes certain charges and exprelated to acquisitions and certain charges and expenses not deemed to reflective of the ongoing operation the Company, as follows (C): Gross profit	used:	=====	23,641	=====	===== 22,96 ===== 23,59 ===== 6
Weighted average shares outstanding to calculate per share information: Basic Diluted Number of operating days (A) Includes certain charges and exprelated to acquisitions and certain charges and express and expenses not deemed to reflective of the ongoing operation the Company, as follows (C): Gross profit Sales and marketing	used:	=====	23,641 ====== 24,251 ===== 63	======	22,96 ===== 23,59 ===== 6
Weighted average shares outstanding to calculate per share information: Basic Diluted Number of operating days (A) Includes certain charges and exprelated to acquisitions and certain charges and expenses not deemed to reflective of the ongoing operation the Company, as follows (C): Gross profit Sales and marketing General and administrative	used:	=====	23,641	======	22,96 ===== 23,59 ===== 6 2,44 71 46
Weighted average shares outstanding to calculate per share information: Basic Diluted Number of operating days (A) Includes certain charges and exprelated to acquisitions and certain charges and expenses not deemed to reflective of the ongoing operation the Company, as follows (C): Gross profit Sales and marketing General and administrative Research and development	used:	=====	23,641 24,251 24,251 63	======	22,96 ===== 23,59 ===== 6 2,44 71 46
Weighted average shares outstanding to calculate per share information: Basic Diluted Number of operating days (A) Includes certain charges and exprelated to acquisitions and certain charges and expenses not deemed to reflective of the ongoing operation the Company, as follows (C): Gross profit Sales and marketing General and administrative	used:	=====	23,641 ====== 24,251 ===== 63	======	22,96 ===== 23,59 ===== 6 2,44 71 46
Weighted average shares outstanding to calculate per share information: Basic Diluted Number of operating days (A) Includes certain charges and exprelated to acquisitions and certain charges and expenses not deemed to reflective of the ongoing operation the Company, as follows (C): Gross profit Sales and marketing General and administrative Research and development	used:	=======================================	23,641 ======= 24,251 ====== 63	======	22,96 ===== 23,59 ==== 6 2,44 71 46 18
Weighted average shares outstanding to calculate per share information: Basic Diluted Number of operating days (A) Includes certain charges and exprelated to acquisitions and certain charges and expenses not deemed to reflective of the ongoing operation the Company, as follows (C): Gross profit Sales and marketing General and administrative Research and development	penses n other be ns of	=======================================	23,641 24,251 =======63 63	\$	22,96 ===== 23,59 ===== 6 2,44 71 46 18
Weighted average shares outstanding to calculate per share information: Basic Diluted Number of operating days (A) Includes certain charges and exprelated to acquisitions and certain charges and exprelated to acquisitions and certain charges and expenses not deemed to reflective of the ongoing operation the Company, as follows (C): Gross profit Sales and marketing General and administrative Research and development Merger costs (B) Includes stock-based compensations	penses n other be ns of	=======================================	23,641 ======= 24,251 ====== 63	\$	22,96 ===== 23,59 ===== 6 2,44 71 46 18
Weighted average shares outstanding to calculate per share information: Basic Diluted Number of operating days (A) Includes certain charges and exprelated to acquisitions and certain charges and exprelated to acquisitions and certain charges and expenses not deemed to reflective of the ongoing operation the Company, as follows (C): Gross profit Sales and marketing General and administrative Research and development Merger costs (B) Includes stock-based compensation expense, as follows (C):	penses n other be ns of	====== ===============================	23,641 ====================================	====== ===============================	22,96 ===== 23,59 ===== 6 2,44 71 46 18 3,80 =====
Weighted average shares outstanding to calculate per share information: Basic Diluted Number of operating days (A) Includes certain charges and exprelated to acquisitions and certain charges and expenses not deemed to reflective of the ongoing operation the Company, as follows (C): Gross profit Sales and marketing General and administrative Research and development Merger costs (B) Includes stock-based compensation expense, as follows (C): Gross profit	penses n other be ns of	====== ===============================	23,641 ====================================	\$	22,96 ===== 23,59 ===== 6 2,44 71 46 18 3,80 =====
Weighted average shares outstanding to calculate per share information: Basic Diluted Number of operating days (A) Includes certain charges and exprelated to acquisitions and certain charges and expenses not deemed to reflective of the ongoing operation the Company, as follows (C): Gross profit Sales and marketing General and administrative Research and development Merger costs (B) Includes stock-based compensation expense, as follows (C): Gross profit Sales and marketing	penses n other be ns of	====== ===============================	23,641 ======= 24,251 ======= 63 - 2,539 - 2,578 =======	\$	22,96 ===== 23,59 ===== 6 2,44 71 46 18 3,80 =====
Weighted average shares outstanding to calculate per share information: Basic Diluted Number of operating days (A) Includes certain charges and exprelated to acquisitions and certain charges and expenses not deemed to reflective of the ongoing operation the Company, as follows (C): Gross profit Sales and marketing General and administrative Research and development Merger costs (B) Includes stock-based compensation expense, as follows (C): Gross profit Sales and marketing General and administrative	penses n other be ns of	====== ===============================	23,641 ======= 24,251 ======= 63 39 - 2,539 - 2,578 =======	\$	22,96 ===== 23,59 ===== 6 2,44 71 46 18 3,80 =====
Weighted average shares outstanding to calculate per share information: Basic Diluted Number of operating days (A) Includes certain charges and exprelated to acquisitions and certain charges and expenses not deemed to reflective of the ongoing operation the Company, as follows (C): Gross profit Sales and marketing General and administrative Research and development Merger costs (B) Includes stock-based compensation expense, as follows (C): Gross profit Sales and marketing	penses n other be ns of	====== ===============================	23,641 ======= 24,251 ======= 63 - 2,539 - 2,578 =======	\$	22,96 ===== 23,59 ===== 6 2,44 71 46 18 3,80 =====
Weighted average shares outstanding to calculate per share information: Basic Diluted Number of operating days (A) Includes certain charges and exprelated to acquisitions and certain charges and expenses not deemed to reflective of the ongoing operation the Company, as follows (C): Gross profit Sales and marketing General and administrative Research and development Merger costs (B) Includes stock-based compensation expense, as follows (C): Gross profit Sales and marketing General and administrative	penses n other be ns of	====== ===============================	23,641 ======= 24,251 ======= 63 39 - 2,539 - 2,578 =======	\$ ====== \$	22,96 ===== 23,59 ===== 6 2,44 71 46 18 3,80 =====

(C) See reconciliation of non-GAAP financial measures in table at end of press release.

DJO Incorporated

Unaudited Condensed Consolidated Statements of Income (In thousands, except per share data and number of operating days)

	Nine Months Ended		
		September 30, 2006	
Net revenues Costs of goods sold (A),(B)	140,841	\$302,293 119,961	
Gross profit Operating expenses:	214,028		
Sales and marketing (A),(B) General and administrative (A),(B) Research and development (A),(B) Amortization of acquired intangibles Merger costs (A)	35,229 6,185		
Total operating expenses	169,238	145,480	
<pre>Income from operations Interest expense and other, net (A)</pre>	44,790 (15,705)	36,852 (15,430)	
Income before income taxes Provision for income taxes		21,422 (9,790)	
Net income		\$ 11,632	
Net income per share: Basic	•	\$ 0.51	
Diluted	\$ 0.67	\$ 0.50	
Non-GAAP diluted net income per share (excluding the impact of purchase accounting adjustments to write up acquired inventories to fair value, certain charges and expenses related to acquisitions and certain other charges and expenses not deemed to be reflective of the ongoing operations of the Company)	\$ 0.93	\$ 0.78	
Weighted average charge outstanding used	·	========	
Weighted average shares outstanding used to			
calculate per share information: Basic		22,620	
Diluted	24,082		
Number of operating days	191	191	

⁽A) Includes purchase accounting

adjustments to write up acquired inventories to fair value, certain charges and expenses related to acquisitions and certain other charges and expenses not deemed to be reflective of the ongoing operations of the Company, as follows (C):

as lullows (C):				
Gross profit	\$	2,851	\$	5,565
Sales and marketing		4,612		1,160
General and administrative		340		1,622
Research and development		-		187
Merger costs		2,539		_
Interest expense and other, net		-		2,529
	\$	10,342	\$	11,063
	=====	======	=====	======
(B) Includes stock-based compensation				
expense, as follows (C):				
Gross profit	\$	812	\$	688
Sales and marketing		3,727		3,175
General and administrative		3,089		2,545
Research and development		421		385
	\$	8,049	\$	6,793
	=====	======	=====	======

(C) See reconciliation of non-GAAP financial measures in table at end of press release.

DJO Incorporated
Unaudited Condensed Consolidated Balance Sheets
(In thousands)

Assets	September 29, 2007	="
Current assets:		
Cash and cash equivalents	\$ 11.956	\$ 7,006
Accounts receivable, net		90,236
Inventories, net	43,422	47,214
Deferred tax asset, current portion Prepaid expenses and other current	10,813	10,797
assets	10,730	14,521
Total current assets		169,774
Property, plant and equipment, net	30,226	32,699
Goodwill, intangible assets and other	425 254	445 610
assets	•	447,610
Deferred tax asset	10,288	18,251
Total assets	\$649,757	\$668,334
	=========	========
Liabilities and stockholders' equity Current liabilities: Accounts payable and other accrued		
liabilities	\$ 55,147	\$ 66,331
Long-term debt, current portion	-	831
Total current liabilities	55,147	67,162

Long-term debt, less current portion	285,500	326,419
Accrued pension	271	201
Other long-term accrued liabilities	5,083	4,283
Total stockholders' equity	303,756	270,269
Total liabilities and stockholders' equity	\$649,757	\$668,334
	=========	========

DJO Incorporated
Unaudited Segment Information
(In thousands, except number of operating days)

	Three Months Ended		Revenues per Day		
	29, 2007	September 30, 2006	29, 2007	30, 2006	
Net revenues:					
Domestic Rehabilitation Regeneration	19,105	15,767	303	250	
International		22,798			
Consolidated net revenues	119,784	113,205	\$1,901	\$1,797	
Gross profit:					
Domestic Rehabilitation	39,897	38,915			
Regeneration	17,705				
International	16,681				
Consolidated gross profit (1)	74,283	67,865			
Income from operations: Domestic Rehabilitation	10 155	11 022			
Regeneration		3,139			
International		4,530			
Income from operations of reportable segments (2) Expenses not allocated to	24,527	18,702			
segments (3)		(4,400)			
Consolidated income from					
operations	\$ 18,266				
Number of operating days	63	63			

(1) GAAP consolidated gross profit for the three months ended September 29, 2007 and September 30, 2006, includes:

Three Months Ended September 29, 2007

Domestic

Rehab Regeneration International

GAAP gross profit Certain charges and expenses related to acquisitions and certain other charges and expenses not deemed to be reflective of the ongoing operations of the Company	\$39,897	\$17,705 -	\$16,681 -
Non-GAAP gross profit (excluding the impact of certain charges and expenses related to acquisitions and certain other charges and expenses not deemed to be reflective of the ongoing	420.005	415 505	416.601
operations of the Company)		\$17,705 ====================================	
		Three Months E September 30,	
	Domestic Rehab		International
GAAP gross profit Certain charges and expenses related to acquisitions and certain other charges and expenses not deemed to be reflective of the ongoing	\$38,915	\$14,428	\$14,522
operations of the Company	2,343	32	67
Non-GAAP gross profit (excluding the impact of certain charges and expenses related to acquisitions and certain other charges and expenses not deemed to be reflective of the ongoing			
operations of the Company)	\$41,258	\$14,460	\$14,589
(2) GAAP income from operations of			or the three
months ended September 29, 2007 a	nd Septemi	ber 30, 2006,	includes:

expenses not deemed to be reflective of the ongoing

	Three Months Ended September 29, 2007		
	Domestic Rehab Regeneration Internationa	.1	
GAAP income from operations of reportable segments Certain charges and expenses related to acquisitions and certain other charges and	\$12,155 \$6,111 \$6,26	1	

Non-GAAP income from operations of reportable segments (excluding the impact of certain charges related to acquisitions and certain other charges and expenses not deemed to be reflective of the ongoing operations of the Company)

> Three Months Ended September 30, 2006

	Domestic Rehab	Regeneration	International
GAAP income from operations of reportable segments Certain charges and expenses related to acquisitions and certain other charges and expenses not deemed to be	\$11,033	\$3,139	\$4,530
reflective of the ongoing			
operations of the Company	3,164	150	399
Non-GAAP income from operations of reportable segments (excluding the impact of certain charges related to acquisitions and			

reportable segments (excluding the impact of certain charges related to acquisitions and certain other charges and expenses not deemed to be reflective of the ongoing operations of the Company)

(3) Expenses not allocated to segments for the three months ended September 29, 2007 and September 30, 2006 include costs not deemed to be reflective of the ongoing operations of the Company of \$2.6 million and \$0.1 million, respectively.

DJO Incorporated Unaudited Segment Information (In thousands, except number of operating days)

	Nine Mon	ths Ended	Revenues	per Day
	September	September	September	September
	29,	30,	29,	30,
	2007	2006	2007	2006
Net revenues:				
Domestic Rehabilitation	\$219,842	\$196,506	\$1,151	\$1,029
Regeneration	55,878	47,953	293	251
International	79,149	57,834	414	303
Consolidated net revenues	354,869	302,293	\$1,858	\$1,583

Gross profit: Domestic Rehabilitation Regeneration International	51,675	44,213 35,152
Consolidated gross profit (1)	214,028	182,332
Income from operations: Domestic Rehabilitation Regeneration International	16,538	30,310 10,560 8,851
<pre>Income from operations of reportable segments (2) Expenses not allocated to segments (3)</pre>	59,755 (14,965)	
Consolidated income from operations	\$ 44,790	\$ 36,852 =======
Number of operating days		191

(1) GAAP consolidated gross profit for the nine months ended September 29, 2007 and September 30, 2006, includes:

	Š	Nine Months E September 29,	
		Regeneration	International
GAAP gross profit Purchasing accounting adjustments to write up acquired inventories to fair value, certain charges and expenses related to acquisitions and certain other charges and expenses not deemed to be reflective of the ongoing	\$112,346	\$51,675	\$50,007
	2,597	30	224
Non-GAAP gross profit (excluding the impact of purchasing accounting adjustments to write up acquired inventories to fair value, certain charges and expenses related to acquisitions and certain other charges and expenses not deemed to be reflective of the ongoing			
operations of the Company)			\$50,231

September	30.	2006

			International
GAAP gross profit Purchasing accounting adjustments to write up acquired inventories to fair value, certain charges and expenses related to acquisitions and certain other charges and expenses not deemed to be reflective of the ongoing	\$102,967	\$44,213	\$35,152
operations of the Company	3,887	32	1,646
Non-GAAP gross profit (excluding the impact of purchasing accounting adjustments to write up acquired inventories to fair value, certain charges and expenses related to acquisitions and certain other charges and expenses not deemed to be reflective of the ongoing	4106.054	444.045	426 500
operations of the Company)			\$36,798 ======

(2) GAAP income from operations of reportable segments for the nine months September 29, 2007 and September 30, 2006, includes:

Nine Months Ended

	i	September 29,	
	Domestic Rehab	Regeneration	International
GAAP income from operations of reportable segments Purchasing accounting adjustments to write up acquired inventories to fair value, certain charges and expenses related to acquisitions and certain other charges and expenses not deemed to be reflective of the ongoing operations of the Company	\$24,821 6,287	, ,	
Non-GAAP income from operations			

of reportable segments (excluding the impact of purchasing accounting adjustments to write up acquired inventories to fair value, certain charges related to acquisitions and certain other charges and expenses not deemed to be reflective of the ongoing operations of the Company) \$ 31,108 \$ 17,241 \$ 18,620

Nine	Mont	hs	Ended
Septer	mber	30,	2006

	Domestic Rehab	Regeneration	International
GAAP income from operations of reportable segments Purchasing accounting adjustments to write up acquired inventories to fair value, certain charges and expenses related to acquisitions and certain other charges and expenses not deemed to be reflective of the ongoing	\$30,310	, ,,,,,,,,	\$8,851
operations of the Company	5,097	150	2,469

Non-GAAP income from operations of reportable segments (excluding the impact of purchasing accounting adjustments to write up acquired inventories to fair value, certain charges related to acquisitions and certain other charges and expenses not deemed to be reflective of the ongoing operations of the Company)

(3) Expenses not allocated to segments for the nine months ended September 29, 2007 and September 30, 2006 include costs not deemed to be reflective of the ongoing operations of the Company of \$3.1 million and \$0.8 million, respectively.

DJO Incorporated
Unaudited Reconciliation of Non-GAAP Financial Measures
(In thousands, except per share data)

In managing its business, the Company makes use of certain non-GAAP financial measures in evaluating the Company's results of operations.

The events giving rise to certain purchase accounting adjustments to write up acquired inventories to fair value, certain charges and expenses related to the Axmed and Aircast acquisitions, costs related to closing the ReAble acquisition and certain other costs and expenses are either not associated with the Company's normal operating business or not reflective of the ongoing business operations of the Company. Costs and expenses that the Company believes are not associated with or reflective of its ongoing business operations include costs related to litigation and arbitration settlements, the write-off of previously deferred expenses related to discontinued acquisitions, the write-off of unamortized deferred debt issuance costs related to the Company's former credit agreement, adjustments related to a complete count of raw material inventories subsequent to the Aircast integration and a charge to increase estimates of bad debts related to aged receivables

due to the current impact of issues encountered in a prior year related to billing and collecting activities.

The Company also records significant non-cash stock-based compensation expense and non-cash amortization expense related to intangible assets acquired.

The Company believes disclosure of non-GAAP gross profit, non-GAAP income from operations, non-GAAP earnings and adjusted EBITDA has economic substance because the expenses excluded from these measures represent non-cash expenditures, or relate to transactions that are not associated with the Company's normal operating business.

The Company believes that presenting non-GAAP diluted earnings per share, excluding the impact of purchase accounting adjustments to write up acquired inventories to fair value, certain charges and expenses related to acquisitions, certain other costs and expenses not deemed reflective of the ongoing business operations of the Company, and adjusted EBITDA are additional measures of performance that investors can use to compare operating results between reporting periods. The Company defines Adjusted EBITDA as earnings before interest, taxes, depreciation, amortization, stock-based compensation expense, purchase accounting adjustments to write up acquired inventory to fair value, certain charges and expenses related to acquisitions and certain other costs and expenses not deemed reflective of the ongoing business operations of the Company. Management of the Company uses non-GAAP information internally in planning, forecasting and evaluating the Company's results of operations in the current period and in comparing it to prior periods. The Company also uses these non-GAAP measures in evaluating management performance for compensation purposes. The Company believes that this information also provides investors better insight in evaluating the Company's earnings performance from core operations and provides consistency in financial reporting.

The measure, "Non-GAAP gross profit" is reconciled with GAAP gross profit in the table below:

Nine Months Ended

Three Months Ended

	TILLEE MO	iiciis Eilded	NITTE MOTI	ciis Elided
		, September 30, 2006		
GAAP gross profit Purchase accounting	\$74,28	3 \$67,865	\$214,028	\$182,332
adjustments to write up acquired inventories				
to fair value, certain				
charges and expenses related to				
acquisitions and certain other charges				

and expenses
not deemed to
be reflective
of the
ongoing
operations of

the Company - 2,442 2,851 5,565

Non-GAAP gross profit (excluding the impact of purchase accounting adjustments to write up acquired inventories to fair value, certain charges and expenses related to acquisitions and certain other charges and expenses not deemed to be reflective of the ongoing operations of the Company)

\$74,283 \$70,307 \$216,879 \$187,897

The measure, "Non-GAAP operating income" is reconciled with GAAP operating income in the table below:

Three Months Ended Nine Months Ended

September 29, September 30, September 29, September 30,
2007 2006 2007 2006

GAAP operating

income \$18,266 \$14,302 \$44,790 \$36,852

Purchase

accounting adjustments

to write up

acquired

inventories

to fair

value,

certain

charges and

expenses related to

acquisitions and certain

```
other charges
and expenses
not deemed to
be reflective
of the
ongoing
operations of
the Company
```

2,578 3,800 10,342 8,534

Non-GAAP operating income (excluding the impact of purchase accounting adjustmentsto write up acquired inventories to fair value, certain charges and expenses related to acquisitions and certain other charges and expenses not deemed to be reflective of the ongoing

operations of

the Company)

related to

The measure, "Non-GAAP net income" is reconciled with GAAP net income in the table below:

	Three	Mon	ths Ended		Nine	Mont	ths Ended	
	September 2007	-	September 2006	-	-	-	September 2006	30,
GAAP net								
income	\$6,	715	\$4,	, 359	\$16	,111	\$11,	632
Purchase								
accounting								
adjustments								
to write up								
acquired								
inventories								
to fair								
value, certain								
charges and								
expenses								
CVLCIINCR								

acquisitions
and certain
other charges
and expenses
not deemed to
be reflective
of the
ongoing
operations of
the Company,
net of tax

1,511 2,281 6,185 6,602

Non-GAAP net income (excluding the impact of purchase accounting adjustments to write up acquired inventories to fair value, certain charges and expenses related to acquisitions and certain other charges and expenses not deemed to be reflective

of the ongoing

operations of

the Company)

inventories
to fair
value,

The measure, "Non-GAAP diluted net income per share" is reconciled with GAAP net income in the table below:

Three Months Ended Nine Months Ended

September 29, September 30, September 29, September 30, 2007 2006

GAAP diluted net income per share \$0.28 \$0.18 \$0.67 \$0.50

Purchase accounting adjustments to write up acquired

certain
charges and
expenses
related to
acquisitions
and certain
other charges
and expenses
not deemed to
be reflective
of the
ongoing
operations of
the Company,
net per share

0.06 0.10 0.26 0.28

diluted net income per share (excluding the impact of purchase accounting adjustments to write up acquired inventories to fair value, certain charges and expenses related to acquisitions, and certain other charges and expenses not deemed to be reflective of the ongoing operations of the Company)

Non-GAAP

\$ 0.34 \$ 0.28 \$ 0.93 \$ 0.78

The measure, "Adjusted EBITDA" is reconciled with GAAP net income in the table below:

Three	Mont	ths Ended		Nine	Mont	ths Ended	
September 2007	29,	September 2006	30,	September 2007	29,	September 2006	30,

GAAP net

income \$6,715 \$4,359 \$16,111 \$11,632

Plus: Interest expense, net of interest

income Provision for	5,321	6,284	16,932	15,684
income taxes	6,552	4,098	12,974	9,790
Depreciation	0,332	1,000	12,011	5,150
and				
amortization	7 621	7 205	22 505	10 645
	7,631	7,395	22,595	18,645
Stock-based				
compensation				
expense	2,997	2,685	8,049	6,793
Purchase				
accounting				
adjustments				
to write up				
acquired				
inventories				
to fair				
value,				
certain				
charges and				
expenses				
related to				
acquisitions				
and certain				
other charges				
and expenses				
not deemed to				
be reflective				
of the				
ongoing				
operations of	0.550	2 000	10 240	0.605
operations of the Company	2,578	3,800	10,342	8,625
the Company	2,578	3,800	10,342	8,625
the Company Adjusted	2,578	3,800	10,342	8,625
the Company Adjusted EBITDA	2,578	3,800	10,342	8,625
the Company Adjusted EBITDA (excluding	2,578	3,800	10,342	8,625
the Company Adjusted EBITDA (excluding the impact of	2,578	3,800	10,342	8,625
Adjusted EBITDA (excluding the impact of purchase	2,578 	3,800	10,342	8,625
Adjusted EBITDA (excluding the impact of purchase accounting	2,578 	3,800	10,342	8,625
Adjusted EBITDA (excluding the impact of purchase accounting adjustments	2,578 	3,800	10,342	8,625
Adjusted EBITDA (excluding the impact of purchase accounting adjustments to write up	2,578	3,800	10,342	8,625
Adjusted EBITDA (excluding the impact of purchase accounting adjustments to write up acquired	2,578	3,800	10,342	8,625
Adjusted EBITDA (excluding the impact of purchase accounting adjustments to write up acquired inventories	2,578	3,800	10,342	8,625
Adjusted EBITDA (excluding the impact of purchase accounting adjustments to write up acquired	2,578	3,800	10,342	8,625
Adjusted EBITDA (excluding the impact of purchase accounting adjustments to write up acquired inventories to fair value,	2,578	3,800	10,342	8,625
Adjusted EBITDA (excluding the impact of purchase accounting adjustments to write up acquired inventories to fair	2,578	3,800	10,342	8,625
Adjusted EBITDA (excluding the impact of purchase accounting adjustments to write up acquired inventories to fair value,	2,578	3,800	10,342	8,625
Adjusted EBITDA (excluding the impact of purchase accounting adjustments to write up acquired inventories to fair value, certain	2,578	3,800	10,342	8,625
Adjusted EBITDA (excluding the impact of purchase accounting adjustments to write up acquired inventories to fair value, certain charges and	2,578	3,800	10,342	8,625
Adjusted EBITDA (excluding the impact of purchase accounting adjustments to write up acquired inventories to fair value, certain charges and expenses	2,578	3,800	10,342	8,625
Adjusted EBITDA (excluding the impact of purchase accounting adjustments to write up acquired inventories to fair value, certain charges and expenses related to	2,578	3,800	10,342	8,625
Adjusted EBITDA (excluding the impact of purchase accounting adjustments to write up acquired inventories to fair value, certain charges and expenses related to acquisitions	2,578	3,800	10,342	8,625
Adjusted EBITDA (excluding the impact of purchase accounting adjustments to write up acquired inventories to fair value, certain charges and expenses related to acquisitions and certain	2,578	3,800	10,342	8,625
Adjusted EBITDA (excluding the impact of purchase accounting adjustments to write up acquired inventories to fair value, certain charges and expenses related to acquisitions and certain other charges	2,578	3,800	10,342	8,625
Adjusted EBITDA (excluding the impact of purchase accounting adjustments to write up acquired inventories to fair value, certain charges and expenses related to acquisitions and certain other charges and expenses	2,578	3,800	10,342	8,625
Adjusted EBITDA (excluding the impact of purchase accounting adjustments to write up acquired inventories to fair value, certain charges and expenses related to acquisitions and certain other charges and expenses not deemed to be reflective	2,578	3,800	10,342	8,625
Adjusted EBITDA (excluding the impact of purchase accounting adjustments to write up acquired inventories to fair value, certain charges and expenses related to acquisitions and certain other charges and expenses not deemed to be reflective of the	2,578	3,800	10,342	8,625
Adjusted EBITDA (excluding the impact of purchase accounting adjustments to write up acquired inventories to fair value, certain charges and expenses related to acquisitions and certain other charges and expenses not deemed to be reflective of the ongoing	2,578	3,800	10,342	8,625
Adjusted EBITDA (excluding the impact of purchase accounting adjustments to write up acquired inventories to fair value, certain charges and expenses related to acquisitions and certain other charges and expenses not deemed to be reflective of the	\$ 31,794	\$ 28,621	\$ 87,003	\$ 71,169

Company Investor/Media Contact:
DJO Incorporated
Mark Francois, Director of Investor Relations
(760) 734-4766
mark.francois@djortho.com

Copyright Business Wire 2007

News Provided by COMTEX